With vaccine sales on the decline, these are tough times for Merck to launch its new pneumococcal shot Capvaxive. | With ...

A series of recommended shots that health providers administer to children as they age has been a recent target of President Donald Trump and his administration.

Pneumococcal disease poses a severe risk to Indian adults, particularly those with chronic health issues. Despite effective ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive results from the Phase 3 STRIDE-13 trial evaluating CAPVAXIVE® (Pneumococcal 21-valent Conjugate ...

Merck & Co. Inc. (NYSE:MRK) on Thursday released results from the Phase 3 STRIDE-13 trial evaluating Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) at the European Society of Clinical ...

Electronic medical records of 42 children with SCD diagnosed between 2009 and 2023 were retrospectively reviewed. Clinical demographic data and pneumococcal serologies were analysed. Of the 42 ...

While the company’s sales outlook was otherwise rosy, Merck took sales hits on Gardisil, Proquad, Varivax and Vaxneuvance.

Infectious disease researchers found the vaccine, used to prevent herpes zoster, or shingles, is also linked to lower risks ...

Several observational analyses suggest higher cardiovascular and dementia risks in those with and without HIV who get ...

Inventprise, a Redmond, Wash.–based biotechnology company developing vaccines for infectious diseases, is laying off 76 ...

In addition to the flu vaccine, the recently updated COVID-19 vaccine and the RSV vaccine are available, as well as vaccines ...